JNJ-42756493
Phase 3Small molecule
Johnson & JohnsonJNJ-42756493 is one of 128 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.
4
Indications
6
Total Trials
0
Active Trials
127
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1JNJ-42756493
Johnson & JohnsonPhase 3
Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Absorption1 trial
Hepatocellular Carcinoma1 trial
Oral1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-42756493. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company